Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Vera Therapeutics, Inc. (NASDAQ:VERA) has been given an average recommendation of “Moderate Buy” by the twelve research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $81.4545.

A number of equities analysts have recently weighed in on VERA shares. Pivotal Research set a $73.00 target price on Vera Therapeutics in a research report on Friday, December 5th. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. Wedbush upped their price objective on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Evercore raised their price objective on shares of Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Finally, HC Wainwright lifted their price objective on shares of Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a report on Monday, March 2nd.

Insider Buying and Selling

In other Vera Therapeutics news, insider Laurence Matthew Skelton sold 1,582 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $66,412.36. Following the completion of the sale, the insider directly owned 64,218 shares of the company’s stock, valued at approximately $2,695,871.64. The trade was a 2.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider William D. Turner sold 2,187 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $91,810.26. Following the completion of the sale, the insider directly owned 45,313 shares of the company’s stock, valued at approximately $1,902,239.74. This trade represents a 4.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,490 shares of company stock worth $1,405,910 over the last ninety days. Insiders own 16.30% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

Institutional investors have recently bought and sold shares of the stock. Capricorn Fund Managers Ltd purchased a new position in Vera Therapeutics during the 3rd quarter worth $13,097,000. Swedbank AB purchased a new stake in shares of Vera Therapeutics in the third quarter valued at about $1,453,000. Squarepoint Ops LLC raised its holdings in shares of Vera Therapeutics by 232.0% in the second quarter. Squarepoint Ops LLC now owns 57,519 shares of the company’s stock valued at $1,355,000 after purchasing an additional 40,196 shares during the last quarter. Bollard Group LLC bought a new position in shares of Vera Therapeutics during the second quarter valued at about $1,509,000. Finally, SG Americas Securities LLC bought a new position in shares of Vera Therapeutics during the third quarter valued at about $911,000. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $40.53 on Friday. Vera Therapeutics has a one year low of $18.53 and a one year high of $56.05. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of -8.70 and a beta of 1.17. The business has a 50-day simple moving average of $43.03 and a 200 day simple moving average of $37.48. The company has a debt-to-equity ratio of 0.12, a current ratio of 13.64 and a quick ratio of 13.64.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same period last year, the company posted ($0.72) earnings per share. On average, research analysts anticipate that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.